Eyeing The Ear: Start-up Decibel Intends To Tackle Inner-Ear Indications

Hearing indications represent a very underserved space for drug therapies, and even the companies that do participate often do so with just a single, isolated program or candidate. Third Rock Ventures thinks it will be able to build the "definitive" inner ear specialist, through internal R&D as well as licensing, with start-up Decibel Therapeutics, which announced a $52m Series A financing on Oct. 15.

More from Anticancer

More from Therapy Areas